Bei Akademie registrieren
Gilead Sciences, US3755581036

Gilead Sciences stock pre-market at EUR 139.88: biopharma group rises slightly

Published on 10/23/2026 at 07:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead develops medicines in virology, oncology and inflammation. At Lang & Schwarz the stock trades pre-market at EUR 139.88 on October 23, 2026, 0.68 percent above the Xetra close of October 22, 2026.

Business and market context

  • Gilead develops medicines across virology, oncology and inflammation.
  • Gilead's U.S. market context is the S&P 500 on October 23, 2026.
  • Gilead Sciences stock trades pre-market at EUR 139.88 at 7:50 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.68 percent above the Xetra close of October 22, 2026.
Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern
Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

The company develops medicines in virology, oncology and inflammation, according to Gilead Sciences. Gilead Sciences stock trades pre-market at EUR 139.88 at 7:50 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.68 percent above the Xetra close of October 22, 2026 (EUR 138.94).

Early indication before Xetra

The stock is EUR 0.94 above the Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.

Business and market setting

Gilead earns revenue from medicines addressing serious diseases, with operations spanning virology, oncology and inflammation, as described by Gilead Sciences. Market context: Market report S&P 500.

More news and analysis on Gilead Sciences stock

Disclaimer...
en | US3755581036 | GILEAD SCIENCES | boerse | 70396645 | bgmi